Age-Related Macular Degeneration (AMD) - National Eye Institute
Jun 22, 2021 · Age-related macular degeneration (AMD) is an eye disease that can blur your central vision. It happens when aging causes damage to the macula — the part of the eye that controls sharp, straight-ahead vision. The macula is part of the retina (the light-sensitive tissue at the back of the eye). AMD is a common condition — it’s a leading ...
AREDS 2 Supplements for Age-Related Macular Degeneration (AMD)
Jun 22, 2021 · Age-related macular degeneration (AMD) is an eye disease that can blur the center of your vision. If you have intermediate AMD in 1 or both eyes, special dietary supplements called AREDS 2 can help slow down vision loss.
Age-Related Macular Degeneration: What You Should Know
This booklet is for people with age-related macular degeneration (AMD) and their families and friends. It provides information about AMD and answers questions about its causes, symptoms, stages and treatment. (26 pages) Topics: AREDS/AREDS2 Age-Related Macular Degeneration Vision Rehabilitation. Material Type:
Macular Edema - National Eye Institute
Nov 15, 2023 · Age-related macular degeneration (AMD). In a certain type of AMD called wet (or neovascular) AMD, abnormal blood vessels in the macula leak fluid into or under the retina, which can cause swelling in the macula. Learn more about AMD. Retinitis pigmentosa (RP). RP is a genetic disease. Some people with RP can also have swelling in the macula.
Treatments for Wet AMD (Advanced Neovascular AMD)
Jun 22, 2021 · Age-related macular degeneration (AMD) is an eye disease that can blur the center of your vision. Wet AMD (also called advanced neovascular AMD) is a serious type of late AMD. It happens when a protein called vascular endothelial growth factor (VEGF) makes abnormal blood vessels grow in the wrong place in the back of your eye.
AREDS/AREDS2 Frequently Asked Questions - National Eye Institute
Moeller SM, Parekh N, et al; CAREDS Research Study Group. Associations between intermediate age-related macular degeneration and lutein and zeaxanthin in the Carotenoids in Age-related Eye Disease Study (CAREDS): ancillary study of the Women's Health Initiative. Arch Ophthalmol. 2006 Aug;124(8):1151-62. doi: 10.1001/archopht.124.8.1151.
Age-Related Eye Disease Studies (AREDS/AREDS2)
Jan 9, 2023 · The Age-Related Eye Disease Study (AREDS) and AREDS2 are major clinical trials sponsored by the National Eye Institute. The AREDS studies were designed to learn more about the natural history and risk factors of age-related macular degeneration (AMD) and cataract and to evaluate the effect of vitamins on the progression of these eye diseases.
Clinical Trial Highlight: Stem Cell Transplants for Dry AMD
Mar 1, 2022 · Age-related macular degeneration (AMD) is a leading cause of vision loss among people 55 years old and older. There is no treatment for geographic atrophy (GA), the advanced stage of dry AMD, in which cells of the retina and associated retinal pigment epithelium (RPE) gradually degenerate and die.
New research offers hope for preventing age-related blindness
Age-related macular degeneration (AMD) is a leading cause of irreversible vision loss in the United States. Despite existing treatments, the underlying causes of this disease and effective therapies remain elusive. New research published in the journal Developmental Cell provides important insights into the cellular mechanisms behind AMD and ...
Story of discovery: NEI-funded research paves way for new dry …
Dec 12, 2023 · Translational Research. NEI. This year, the Food and Drug Administration (FDA) approved Syfovre (pegcetacoplan) and Izervay (avacincaptad pegol), the very first drugs for treating geographic atrophy (GA), also known as late-stage “dry” age-related macular degeneration (AMD). Both drugs target the immune system’s complement pathway, and ...